An evaluation of the clinical impacts of 7-day platelets.


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
03 2023
Historique:
revised: 29 11 2022
received: 03 10 2022
accepted: 02 12 2022
pubmed: 7 2 2023
medline: 23 3 2023
entrez: 6 2 2023
Statut: ppublish

Résumé

In August 2017, Canadian Blood Services extended the shelf-life of platelet concentrates from 5 to 7 days. The clinical impacts of this policy change remain unclear. We used a before-after retrospective design of platelet-transfused adult inpatients in Hamilton, ON, Canada. Data were captured for 18 months before (Period 1: February 2016-July 2017) and 18 months after (Period 2: September 2017-February 2019) 7-day platelet implementation. Primary outcome was absolute platelet count increment (ACI) in univariate and multivariate analyses adjusted for confounders. Data were obtained from our institution's transfusion database, Ontario's Transfusion Transmitted Injuries Surveillance System, and the blood supplier. Overall, 1360 patients with single dose platelet transfusions were included in Period 1 and 1211 patients in Period 2. Median age at admission was 66 years, and approximately 40% of patients underwent cardiac surgery. Using a non-inferiority margin of -10 × 10 Platelet transfusions following 7-day storage policy were non-inferior to transfusions in the 5-day policy period, although reduced ACIs were observed. There were no increases in adverse clinical outcomes.

Sections du résumé

BACKGROUND
In August 2017, Canadian Blood Services extended the shelf-life of platelet concentrates from 5 to 7 days. The clinical impacts of this policy change remain unclear.
STUDY DESIGN AND METHODS
We used a before-after retrospective design of platelet-transfused adult inpatients in Hamilton, ON, Canada. Data were captured for 18 months before (Period 1: February 2016-July 2017) and 18 months after (Period 2: September 2017-February 2019) 7-day platelet implementation. Primary outcome was absolute platelet count increment (ACI) in univariate and multivariate analyses adjusted for confounders. Data were obtained from our institution's transfusion database, Ontario's Transfusion Transmitted Injuries Surveillance System, and the blood supplier.
RESULTS
Overall, 1360 patients with single dose platelet transfusions were included in Period 1 and 1211 patients in Period 2. Median age at admission was 66 years, and approximately 40% of patients underwent cardiac surgery. Using a non-inferiority margin of -10 × 10
CONCLUSION
Platelet transfusions following 7-day storage policy were non-inferior to transfusions in the 5-day policy period, although reduced ACIs were observed. There were no increases in adverse clinical outcomes.

Identifiants

pubmed: 36744999
doi: 10.1111/trf.17272
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

480-493

Informations de copyright

© 2023 AABB.

Références

Satake M, Kozakai M, Matsumoto M, Matsubayashi K, Taira R, Goto N. Platelet safety strategies in Japan: impact of short shelf life on the incidence of septic reactions. Transfusion. 2020;60(4):731-8.
Prax M, Bekeredjian-Ding I, Krut O. Microbiological screening of platelet concentrates in Europe. Transfus Med Hemother. 2019;46(2):76-86.
de Korte D. 10 years experience with bacterial screening of platelet concentrates in The Netherlands. Transfus Med Hemother. 2011;38(4):251-4.
Thyer J, Perkowska-Guse Z, Ismay SL, Keller AJ, Chan HT, Dennington PM, et al. Bacterial testing of platelets - has it prevented transfusion-transmitted bacterial infections in Australia? Vox Sang. 2018;113(1):13-20.
Infanti L, Holbro A, Passweg J, Bolliger D, Tsakiris DA, Merki R, et al. Clinical impact of amotosalen-ultraviolet a pathogen-inactivated platelets stored for up to 7 days. Transfusion. 2019;59(11):3350-61.
Ramirez-Arcos S, Evans S, McIntyre T, Pang C, Yi QL, DiFranco C, et al. Extension of platelet shelf life with an improved bacterial testing algorithm. Transfusion. 2020;60(12):2918-28.
Seghatchian J, Krailadsiri P. The platelet storage lesion. Transfus Med Rev. 1997;11(2):130-44.
Cauwenberghs S, van Pampus E, Curvers J, Akkerman JW, Heemskerk JW. Hemostatic and signaling functions of transfused platelets. Transfus Med Rev. 2007;21(4):287-94.
McVey MJ, Weidenfeld S, Maishan M, et al. Platelet extracellular vesicles mediate transfusion-related acute lung injury by imbalancing the sphingolipid rheostat. Blood. 2021;137(5):690-701.
Tissot JD, Bardyn M, Sonego G, Abonnenc M, Prudent M. The storage lesions: from past to future. Transfus Clin Biol. 2017;24(3):277-84.
Aubron C, Flint AWJ, Ozier Y, McQuilten Z. Platelet storage duration and its clinical and transfusion outcomes: a systematic review. Crit Care. 2018;22(1):185.
Diedrich B, Ringden O, Watz E, Shanwell A. A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients. Vox Sang. 2009;97(3):254-9.
Dijkstra-Tiekstra MJ, Pietersz RN, Hendriks EC, Reesink HW, Huijgens PC. In vivo PLT increments after transfusions of WBC-reduced PLT concentrates stored for up to 7 days. Transfusion. 2004;44(3):330-6.
Akkok CA, Brinch L, Lauritzsen GF, Solheim BG, Kjeldsen-Kragh J. Clinical effect of buffy-coat vs. apheresis platelet concentrates in patients with severe thrombocytopenia after intensive chemotherapy. Vox Sang. 2007;93(1):42-8.
Kerkhoffs JL, van Putten WL, Novotny VM, te Boekhorst PA, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol. 2010;150(2):209-17.
MacLennan S, Harding K, Llewelyn C, Choo L, Bakrania L, Massey E, et al. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets. Transfusion. 2015;55(8):1856-65. quiz 1855.
Kaplan A, Lindgren B, Marschner S, Aznar M, Zalba S, Sánchez P, et al. Evaluation of the post-transfusion platelet increment and safety of riboflavin-based pathogen reduction technology (PRT) treated platelet products stored in platelet additive solution for 5 days or less versus 6-7 days. Transfus Apher Sci. 2016;54(2):248-52.
Dijkstra-Tiekstra MJ, van de Watering LM, Rondeel JM, Slomp J, de Wildt-Eggen J. Implementation of a new platelet pooling system for platelet concentrates led to a higher corrected count increment after transfusion: a comparative observational study of platelet concentrates before and after implementation. Transfus Med. 2014;24(2):99-104.
Tynngård N, Boknäs N, Trinks M, Dreimane A, Berlin G. Storage-induced change in platelet transfusion response evaluated by serial transfusions from one donor to one patient. Transfusion. 2019;59(2):723-8.
Brixner V, Bug G, Pohler P, Krämer D, Metzner B, Voss A, et al. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial. Haematologica. 2021;106(4):1086-96.
Ning S, Barty R, Liu Y, Heddle NM, Rochwerg B, Arnold DM. Platelet transfusion practices in the ICU: data from a large transfusion registry. Chest. 2016;150(3):516-23.
Ning S, Liu Y, Barty R, Cook R, Rochwerg B, Iorio A, et al. The association between platelet transfusions and mortality in patients with critical illness. Transfusion. 2019;59(6):1962-70.
Yanagawa B, Ribeiro R, Lee J, Mazer CD, Cheng D, Martin J, et al. Platelet transfusion in cardiac surgery: a systematic review and meta-analysis. Ann Thorac Surg. 2021;111(2):607-14.
Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010;362(7):600-13.
Welsby IJ, Lockhart E, Phillips-Bute B, Campbell ML, Mathew JP, Newman MF, et al. Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion. 2010;50(11):2311-7.
Flint A, Aubron C, Bailey M, Bellomo R, Pilcher D, Cheng AC, et al. Duration of platelet storage and outcomes of critically ill patients. Transfusion. 2017;57(3):599-605.
Inaba K, Branco BC, Rhee P, Blackbourne LH, Holcomb JB, Spinella PC, et al. Impact of the duration of platelet storage in critically ill trauma patients. J Trauma. 2011;71(6):1766-73; discussion 1773-1764.
Pandey S, Belanger GA, Rajbhandary S, Cohn CS, Benjamin RJ, Bracey AW, et al. A survey of US hospitals on platelet inventory management, transfusion practice, and platelet availability. Transfusion. 2021;61(9):2611-20.
Harm SK, Szczepiorkowski ZM, Dunbar NM. Routine use of day 6 and day 7 platelets with rapid testing: two hospitals assess impact 1 year after implementation. Transfusion. 2018;58(4):938-42.
Hay SN, Immel CC, McClannan LS, Brecher ME. The introduction of 7-day platelets: a university hospital experience. J Clin Apher. 2007;22(5):283-6.
Hendrickson JE, Roubinian NH, Chowdhury D, Brambilla D, Murphy EL, Wu Y, et al. Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion. 2016;56(10):2587-96.

Auteurs

Shuoyan Ning (S)

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
Canadian Blood Services, Ancaster, Ontario, Canada.
Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Nadia Gabarin (N)

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Na Li (N)

Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.

Yang Liu (Y)

Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.

Kayla Lucier (K)

Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.

Rebecca Barty (R)

Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.

Jason Acker (J)

Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Canadian Blood Services, Centre of Innovation, Ottawa, Ontario, Canada.

Kathryn E Webert (KE)

Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
Canadian Blood Services, Ancaster, Ontario, Canada.
Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Theodore E Warkentin (TE)

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
Department of Pathology and Molecular Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

Donald M Arnold (DM)

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.

Nancy M Heddle (NM)

Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Department of Medicine, McMaster Centre for Transfusion Research, McMaster University, Hamilton, Ontario, Canada.
Canadian Blood Services, Centre of Innovation, Ottawa, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH